Skip to content
Fischer Medical Ventures logo

Fischer Medical Ventures

FISCHER NSE
₹25.23 +0.60 (+2.44%)
P/E
66.39
View as Markdown
MCP
Close 4 Nov 2026 ₹25.23 −71.31 −73.9% 1Y
Start ₹96.54

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
11.40%
Debt to Equity
0.28
EPS (TTM)
₹0.38
Book Value
₹6.99
Market Cap
—
P/E (TTM)
66.39
P/B
3.61
ROE
8.91%
Dividend Yield
0.20%
EBITDA
₹55.40 Cr
52W High
₹99.00
52W Low
₹21.78
Day Range
₹23.50 – ₹26.95
Volume
28,89,856

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

44 Weak

Data confidence 98/100

Category scores

Quality
31
Poor
Returns, margins, earnings quality 22% weight
Valuation
34
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
47
Average
Solvency, leverage, coverage 9% weight
Momentum
15
Poor
Trend strength, vol-adjusted 12% weight
Ownership
66
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Promoter holding has increased by 0.94% over last quarter.

Weaknesses

3
  • Stock is trading at 5.51 times its book value
  • Company has a low return on equity of 5.74% over last 3 years.
  • Company has high debtors of 342 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1351
OscillatorsBearish351
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
35.14
Neutral
MACD (12,26,9)
−2.18
Bearish
SMA (50)
31.88
Bearish
SMA (200)
36.29
Bearish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
3YZero base
1Y+177.48%
TTM+195.82%

Net profit

Net profit growth by window
3YZero base
1YTiny base
TTM+296.76%

Operating cash flow

Operating cash flow growth by window
3Y—
1YOutflow widened by ₹15 Cr
TTM—

3Y: The statements do not go back far enough for this window.

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
3YNo sales
1Y+11.26 pp
TTM+6.40 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹0.00 Cr
Mar 2024₹21.00 Cr
Mar 2025₹111 Cr
Mar 2026₹308 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹0.00 Cr
Mar 2024₹2.00 Cr
Mar 2025₹1.00 Cr
Mar 2026₹31.00 Cr

Quarterly Results

₹ Cr
FISCHER quarterly results, ₹ crore
Particulars Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
20.79
10.12
39.66
11.75
49.17
23.44
86.31
101
97.54
81.92
Expenses
0
18.28
10.33
39.16
11.38
46.66
19.45
70.09
79.53
101
70.67
Operating Profit
0
2.51
−0.21
0.5
0.37
2.51
3.99
16.22
21.57
−3.77
11.25
OPM %
—
12.07%
−2.08%
1.26%
3.15%
5.1%
17.02%
18.79%
21.34%
−3.87%
13.73%
Other Income
0
0.47
0.69
0.05
0.38
0.15
7.47
2.48
1.09
0.77
1.48
Interest
0
0.05
0.13
0.05
0.07
0.23
0.66
0.92
0.64
3.66
3.54
Depreciation
0
0.18
0.28
0.29
0.56
0.51
0.77
0.51
0.77
0.93
1.36
PBT
0
2.75
0.07
0.21
0.12
1.92
10.03
17.27
21.25
−7.59
7.83
Tax %
—
6.18%
271.43%
−38.1%
350%
26.04%
51.55%
19.46%
9.18%
64.03%
51.6%
Net Profit
0
2.59
−0.12
0.29
−0.29
1.31
4.86
13.9
19.23
−12.44
3.79
EPS (₹)
0
0.05
0
0.01
−0.01
0.02
0.07
0.21
0.3
−0.19
0.06

Profit & Loss

₹ Cr
FISCHER profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
21
111
309
367
Expenses
0
19
107
265
322
Operating Profit
0
2
3
43
45
OPM %
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
9%
3%
14%
12%
Other Income
0
0
1
12
6
Interest
0
0
0
6
9
Depreciation
0
0
2
3
4
PBT
0
2
3
47
39
Tax %
—
13%
37%
33%
—
Net Profit
0
2
1
31
24
EPS (₹)
−0.24
0.03
0.02
0.49
0.38
Div. Payout %
0%
0%
22%
1%
—

Balance Sheet

₹ Cr
FISCHER balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.17
54
64
65
Reserves
0
28
274
320
Borrowings
1
2
85
107
Other Liabilities
0
4
34
179
Total Liabilities
0
86
457
671
Fixed Assets
0
15
24
32
CWIP
0
0
1
3
Investments
0
1
7
118
Other Assets
0
70
425
519
Total Assets
0
86
457
671

Cash Flow

₹ Cr
FISCHER cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
−7
−86
−101
Investing
—
−29
−125
−5
Financing
—
37
315
14
Net Cash Flow
—
1
103
−92
Free Cash Flow
—
−8
−91
6
CFO/OP
—
−392
−2,555
−194

Ratios

FISCHER financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
398
251
342
Inventory Days
—
99
36
58
Days Payable
—
48
82
466
Cash Conversion Cycle
—
449
205
−67
Working Capital Days
—
498
42
159
ROCE %
—
5%
1%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Fischer Medical Ventures insights

61 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.08%
  • Public 22.82%
  • FIIs 6.71%
  • Others 6.12%
  • DIIs 1.26%

6.81% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Documents

  • Concall · Sep 2026
    PPT
  • Concall · Sep 2026
    PPT
  • Q2 FY26 concall · Nov 2025
    Transcript PPT
  • Concall · Dec 2024
    PPT

Frequently Asked Questions about Fischer Medical Ventures

What does Fischer Medical Ventures Ltd do?
Fischer Medical Ventures Ltd, earlier known as Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides AI-based health screening and digital-health solutions.
Where is Fischer Medical Ventures Ltd (FISCHER) listed?
Fischer Medical Ventures Ltd trades as FISCHER on the NSE and under code 524743 on the BSE.
Which sector does Fischer Medical Ventures Ltd belong to?
Fischer Medical Ventures Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the PE ratio of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd trades at a PE ratio of 66.39 as of 4 Nov 2026, on earnings per share of ₹0.38, against a book value of ₹6.99 per share.
What is the 52-week high and low of Fischer Medical Ventures Ltd?
Over the last 52 weeks Fischer Medical Ventures Ltd has traded between ₹21.78 and ₹99 as of 4 Nov 2026.
Does Fischer Medical Ventures Ltd pay dividends?
Fischer Medical Ventures Ltd has a dividend yield of 0.20%.
What is the Return on Equity (ROE) of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd reported a return on equity of 8.91%. Its debt-to-equity ratio is 0.28.

Company Information

Fischer Medical Ventures Ltd, earlier known as Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam.

Website fischermv.com
CEO Mr. Ravindran Govindan LLB
Employees 40
Listed 8 Jun 2005
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FISCHER.md for Fischer Medical Ventures Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Healthcare Equipment stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month